Other Clinical Trial - Prone Position During ECMO in Pediatric Patients

Status Not yet recruiting

Clinical Trial Summary

In 2023, the second Pediatric Acute Lung Injury Consensus Conference (PALICC-2) updated the diagnostic and management guidelines for Pediatric Acute Respiratory Distress Syndrome (PARDS). The guidelines do not provide sufficient evidence-based recommendations on whether prone positioning ventilation is necessary for severe PARDS patients. However, the effectiveness of Extracorporeal Membrane Oxygenation (ECMO) in treating severe PARDS has been fluctuating around 70% according to recent data from Extracorporeal Life Support Organization (ELSO). In 2018, the Randomized Evaluation of Sedation Titration for Respiratory Failure (RESTORE) study group conducted a retrospective analysis and concluded that ECMO does not significantly improve survival rates for severe PARDS. However, this retrospective study mainly focused on data from North America, with significant variations in annual ECMO support cases among different centers, which may introduce bias. With advancements in ECMO technology and materials, ECMO has become safer and easier to operate. In recent years, pediatric ECMO support technology has rapidly grown in mainland China and is increasingly being widely used domestically to rescue more children promptly. ECMO can also serve as a salvage measure for severely ARDS children who have failed conventional mechanical ventilation treatment. When optimizing ventilator parameters (titrating positive end expiratory pressure (PEEP) levels, neuromuscular blockers, prone positioning), strict fluid management alone cannot maintain satisfactory oxygenation (P/F<80mmHg or Oxygen Index (OI) >40 for over 4 hours or OI >20 for over 24 hours), initiating ECMO can achieve lung-protective ventilation strategies with ultra-low tidal volumes to minimize ventilator-associated lung injury.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Acute Lung Injury
Extracorporeal Membrane Oxygenation
Pediatric Acute Respiratory Distress Syndrome
Respiratory Distress Syndrome
Respiratory Distress Syndrome, Newborn
Syndrome

Clinical Trial Details

NCT number	NCT06369584
Study type	Interventional
Source	Seventh Medical Center of PLA General Hospital
Contact	Xiaoyang Hong, M.D.
Phone	13311057633
Email	jyhongxy@163.com
Status	Not yet recruiting
Phase	N/A
Start date	May 1, 2024
Completion date	July 1, 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03685383` - Cytokine Adsorption in Post-cardiac Arrest Syndrome in Patients Requiring Extracorporeal Cardiopulmonary Resuscitation	N/A
Not yet recruiting	`NCT05106491` - Efficacy and Safety of Synchronized Cardiac Support in Cardiogenic Shock Patients	N/A
Recruiting	`NCT05699005` - Individualized or Conventional Transfusion Strategies During Peripheral VA-ECMO	Phase 1
Recruiting	`NCT05444764` - PREdiCtIon of Weanability, Survival and Functional outcomEs After ECLS
Completed	`NCT05038943` - Evaluation of Safety and Effectiveness of The SherpaPak in Donation After Circulatory Death Heart Transplantation	N/A
Not yet recruiting	`NCT05341687` - Prognostic Value of Respiratory System Compliance Under VV-ECMO on 180-day Mortality in COVID-19 ARDS.
Suspended	`NCT04385771` - Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation	N/A
Recruiting	`NCT03766282` - Pharmacokinetics in Extracorporeal Membrane Oxygenation
Completed	`NCT03355625` - Platelet Function During Extracorporeal Membrane Oxygenation in Adult Patients
Completed	`NCT01521195` - Oxygen Consumption In Critically Ill Children	N/A
Recruiting	`NCT04620070` - ON-SCENE Initiation of Extracorporeal CardioPulmonary Resuscitation During Refractory Out-of-Hospital Cardiac Arrest	N/A
Recruiting	`NCT06062212` - Effect of Transpulmonary MP on Prognosis of Patients With Severe ARDS Treated With VV-ECMO
Recruiting	`NCT05730114` - Monitoring Antiplatelet Drugs in Cardiac Arrest Patients
Completed	`NCT05154071` - Impact of the Implementation of a Referral Veno-venous Extracorporeal Membrane Oxygenation Centre on Mortality
Recruiting	`NCT04536272` - Reduced Anticoagulation Targets in ECLS (RATE)	Phase 3
Completed	`NCT05693051` - Use of Prone Position Ventilation in Danish Patients With COVID-19 Induced Severe ARDS Treated With VV-ECMO
Completed	`NCT03764319` - Low Frequency, Ultra-low Tidal Volume Ventilation in Patients With ARDS and ECMO	N/A
Recruiting	`NCT05762029` - Treatment of Extracorporeal Membrane Oxygenation in Severe Poisoning
Completed	`NCT02995811` - Characterising Changes in Muscle Quantity and Quality in Patients Requiring ECMO Oxygen During Critical Illness
Recruiting	`NCT04754854` - Reduction of Blood Recirculation in Veno-Venous ECMO

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Prone Position During ECMO in Pediatric Patients With Severe ARDS — PEPAD

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms